Peter Clark, MA, MD, FRCP: A Payer Perspective

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Varsha Gandhi, PhD, on Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Dec

Today In Oncology

Peter Clark, MA, MD, FRCP: A Payer Perspective

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Varsha Gandhi, PhD, on Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups

Outcomes Associated With Consensus Molecular Subtypes in First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer

Addition of Pirfenidone to Glucocorticoids in Grade 2 or 3 Radiation-Induced Lung Injury

Lung Cancer Screening Criteria NELSON vs PLCOm2012

ADCs vs Standard Chemotherapy: Cardiotoxicity in HER2-Positive Advanced Breast Cancer